Abstract: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.

Abstract: The present invention pertains to a process for the preparation of a fast-disintegrating tablet (30) containing a medicinal substance, comprising the steps of providing a fluid formulation comprising the medicinal substance, providing a solid element (100) having formed therein at least one cavity, (101) cooling the solid element (100) to a temperature below a freezing temperature of the formulation, filling the cavity with the fluid formulation, solidifying the formulation while present in the cavity (101) to form a solid pellet comprising the medicinal substance without actively shaping the entire surface of the pellet, taking the pellet out of the cavity and drying the pellet in a vacuum to obtain the tablet. The invention also pertains to a system for performing such a process and a package containing the resulting tablet.

Abstract: This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

Abstract: The present invention pertains to a vaccine comprising in combination non-live antigens of Lawsonia intracellularis, of Mycoplasma hyopneumniae and Porcine circo virus, and a pharmaceutically acceptable carrier. The invention also pertains to a kit comprising a first container having contained therein non-live antigens of Lawsonia intracellularis, one or more other containers having contained therein Mycoplasma hyopneumoniae and Porcine circo virus antigens and instructions for mixing the antigens of Lawsonia intracellularis, Mycoplasma hyopneumoniae, and Porcine circo virus to formulate one combination vaccine suitable for systemic vaccination.

Abstract: The present invention relates to a method of culturing bacterial organisms belonging to the family Anaplasmataceae in mammalian embryonic or fetal cells. In particular, the present invention is directed to growth of bacterial organisms belonging to the family Anaplasmataceae including organisms belonging to the Anaplasma, Ehrlichia and Neorickettsia genera. The bacterial organisms may be cultured in mammalian embryonic or fetal host cells including feline embryonic host cells. Bacterial material cultured according to the methods described herein may be used as the basis for vaccines against diseases associated with the Anaplasmataceae bacteria, or as the basis for diagnostic applications useful for diagnosing diseases associated with the Anaplasmataceae bacteria.

Abstract: The current invention pertains to an aqueous composition containing a biological antigen and an acrylic acid polymer, wherein the composition comprises an electrolyte to provide an osmolarity higher than the osmolarity of a 0.9% (w/v) sodium chloride solution in water. The invention also pertains to the acrylic acid polymer for use in a one shot vaccine against porcine circo virus 2 (PCV2) and optionally Mycoplasma hyopneumoniae and in an aqueous composition for reducing fever induced by the biological antigens present in the aqueous composition when the composition is administered to a subject animal.

Abstract: A method for fastening a thread (24) to a tampon (10), in particular a veterinary tampon, comprising the steps of passing the thread through the tampon by means of a needle (12, 14), and knotting the loose ends of the thread, wherein that the step of passing the thread through the tampon comprises: -piercing the tampon (10) with two hollow needles (12, 14), -inserting the distal ends of the needles into a mould (20) that forms a passage (16) interconnecting the open ends of the hollow needles, feeding the thread (24) to the proximal end of one (12) of the two needles, -applying a suction pressure to the proximal end of the other (14) of the two needles, -opening the mould (20), and -withdrawing the needles (12, 14) from the tampon (10).

Abstract: The invention relates to a recombinant classical swine fever virus (CSFV). A preferred recombinant CSFV comprises a deletion of at least one amino acid in a “TAVSPTTLR” domain of the E2 protein. The invention further relates to a vaccine comprising the recombinant CSFV, a method for generating a recombinant CSFV, and use of a recombinant CSFV.

Abstract: The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.

Abstract: The present invention relates to a stabilizer composition comprising an amino acid, and a sugar wherein all compounds are chemically defined; to a vaccine composition comprising such a stabilizer composition and a biological molecule and/or a micro-organism; to a method for preparing a pharmaceutical composition comprising admixing such a stabilizer composition with a biological molecule and/or a micro-organism; to the use of such a stabilizer composition, and of vaccines prepared therewith.

Abstract: This invention is directed to a pharmaceutical composition for drinking water administration comprising benzimidazole carbamate particles having an effective average particle size of less than 450 mm and a Tween-type surfactant; a method for making the composition; use of the composition to make a medicament for controlling parasites; and use of said composition for the manufacture of a medicament or protecting animal from parasitic infection.

Abstract: A tube weld seam test method and device for testing a tube weld seam (32) of a flexible tube (18) for leaks having: a first pinching device (10) and a second pinching device (12) for pinching closed the flexible tube (18) at a first position (A) and at a second position (B), the weld seam to be tested being arranged between the first and second positions (A; B); a compressing mechanism arranged for partly compressing a tube section enclosed between the first and second pinching devices (10; 12); and a pressure test device (14) arranged for testing an internal pressure of said tube section in order to test the tube weld seam for leaks.

Abstract: The present invention pertains to the identification and initial characterization of CctA, a novel, secreted toxin of Clostridium chauvoei that represents the major cytotoxic activity of C. chauvoei. This toxin confers C. chauvoei its characteristic strong hemolytic activity towards erythrocytes of various species, since anti-CctA antibodies fully neutralize hemolysis by C. chauvoei on standard blood-agar medium or in cell-free supernatants of liquid cultures.

Abstract: Injectable veterinary composition comprising a fluorinated chloramphenicol or thiamphenicol derivative and a solvent system comprising an ether of 1,2-ethanediol oligo- or polymers, and a pyrrolidone solvent.

Abstract: This invention is directed generally to a process for producing Zeranol that eliminates high pressure and high temperature hydrogenations and provides high selectivity for Zeranol at improved yields.

Abstract: This invention relates to a process for the hydrogenation of a ketooxime to selectively form an aminoalcohol stereoisomer, and, in particular, to a process for the hydrogenation of 4,5-dihydro-imidazo[4,5,1-jk][1]benzazepin-2,6,7[1H]-trione-6-oxime or a salt thereof to selectively form a stereoisomer of 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1H]-one or a salt thereof. This invention also relates to the use of the 6-amino-7-hydroxy-4,5,6,7-tetrahydro-imidazo[4,5,1-jk][1]-benzazepin-2[1H]-one hydrogenation product or a salt thereof to selectively make a stereoisomer of zilpaterol or a salt thereof, as well as the use of such a zilpaterol stereoisomer or salt in methods of treatment and medicaments for animals.

Abstract: The present invention pertains to the use of Streptococcus suis antigens corresponding to Streptococcus suis bacteria of a predetermined serotype in the manufacture of a vaccine for administration to a sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt, against a disorder arising from Streptococcus suis bacteria of a serotype other than the predetermined one. The invention also pertains to Streptococcus suis antigens for use in the manufacture of such a vaccine.

Abstract: The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.

Abstract: The present invention pertains to a method to produce RTX-toxin Apxl by culturing Actinobacillus pleuropneumoniae bacteria in a liquid culturing medium that supports growth of the bacteria, to which medium a calcium salt is added to form calcium ions in the medium, wherein the culturing medium contains borogluconate to form a calcium borogluconate complex in the medium.

Abstract: The invention pertains to a pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes having the ability to survive within macrophages of the animal, comprising live bacteria of a nocardioform actinomycetes species, the live bacteria being attenuated by inactivation of a gene that encodes a protein involved in methylhexahydroindanedione propionate degradation, and a pharmaceutically acceptable carrier for these live bacteria.